Display options
Cite
Rich NE, Parikh ND, Singal AG. Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. Curr Treat Options Gastroenterol. 2017;15(2):296-304doi: 10.1007/s11938-017-0133-3.
Rich, N. E., Parikh, N. D., & Singal, A. G. (2017). Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. Current treatment options in gastroenterology, 15(2), 296-304. https://doi.org/10.1007/s11938-017-0133-3
Rich, Nicole E, et al. "Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices." Current treatment options in gastroenterology vol. 15,2 (2017): 296-304. doi: https://doi.org/10.1007/s11938-017-0133-3
Rich NE, Parikh ND, Singal AG. Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. Curr Treat Options Gastroenterol. 2017 Jun;15(2):296-304. doi: 10.1007/s11938-017-0133-3. PMID: 28425018.
Copy Download .nbib Format: NLM
Share it on

Curr Treat Options Gastroenterol. 2017 Jun;15(2):296-304. doi: 10.1007/s11938-017-0133-3.

Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices.

Current treatment options in gastroenterology

Nicole E Rich, Neehar D Parikh, Amit G Singal

Affiliations

  1. Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
  2. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
  3. Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA. [email protected].
  4. Liver Tumor Program, Division of Digestive and Liver Diseases, University of Texas Southwestern, 5959 Harry Hines Blvd, POB 1, Suite 420, Dallas, TX, 75390-8887, USA. [email protected].

PMID: 28425018 DOI: 10.1007/s11938-017-0133-3

Abstract

OPINION STATEMENT: Benefits of liver transplantation (LT) for patients with hepatocellular carcinoma (HCC) are well established. However, there is debate regarding optimal and equitable selection of patients best served by LT, particularly in the face of limited organ availability. Herein, we discuss topics regarding LT selection criteria for patients with HCC. Recent change in UNOS policy currently mandates a 6-month observation period prior to priority listing and institutes a cap of 34 MELD exception points for patients with HCC. Additionally, two further proposed changes to UNOS policy include (1) requiring locoregional therapy for those with small (2-3 cm) unifocal HCC prior to applying for exception points and (2) allowing downstaging in select patients with UNOS T3 lesions. These policies move beyond simply using tumor burden to using markers of tumor biology for selecting patients who have the lowest risk of post-transplant recurrence and best chance at long-term post-transplant survival. Given increasing time on transplant waiting lists and shortage of donor grafts, LT should be reserved for patients who may achieve significant benefit compared to non-transplant therapies. Potential benefit to HCC patients must be weighed against the harm from delaying or precluding LT for non-HCC patients on the waiting list, particularly in regions with limited donor availability. The relative benefit of LT in patients with small (<3 cm) HCC is likely limited; surgical resection (in absence of portal hypertension) and local ablative therapy (if portal hypertension present) are both efficacious and more cost-effective and should likely be regarded as first line therapies for these patients. Salvage LT can be considered as a rescue option for those with recurrent disease. Downstaging for selected patients with UNOS T3 lesions may identify those with good tumor biology and acceptable post-transplant outcomes; however, current studies have had a wide variation in reported outcomes. While awaiting more data, a standardized downstaging protocol including a priori inclusion criteria and a mandatory waiting time prior to LT to observe tumor biology likely yields the best outcomes.

Keywords: Cirrhosis; Downstaging; Hepatocellular carcinoma; Liver cancer; Liver transplantation; Milan criteria; UNOS policy

References

  1. Hepatology. 2009 Feb;49(2):453-9 - PubMed
  2. Ann Surg. 2007 Sep;246(3):502-9; discussion 509-11 - PubMed
  3. Am J Transplant. 2010 Sep;10(9):2092-8 - PubMed
  4. Transplantation. 2014 Jan 27;97(2):227-34 - PubMed
  5. Hepatology. 2001 Jun;33(6):1394-403 - PubMed
  6. Liver Transpl. 2016 Feb;22(2):178-87 - PubMed
  7. Hepatology. 2014 Dec;60(6):1957-62 - PubMed
  8. Clin Transplant. 2013 Mar-Apr;27(2):311-8 - PubMed
  9. Cancer. 2012 Apr 1;118(7):1838-44 - PubMed
  10. Clin Gastroenterol Hepatol. 2011 Jan;9(1):79-86 - PubMed
  11. Liver Transpl. 2011 Oct;17 Suppl 2:S44-57 - PubMed
  12. J Hepatol. 2012 Feb;56(2):412-8 - PubMed
  13. Hepatology. 2016 Dec;64(6):2077-2088 - PubMed
  14. Liver Transpl. 2006 Oct;12 (10 ):1504-11 - PubMed
  15. Eur J Med Res. 2007 Oct 30;12(10):527-34 - PubMed
  16. Lancet Oncol. 2009 Jan;10(1):35-43 - PubMed
  17. Liver Transpl. 2010 Oct;16(10):1186-94 - PubMed
  18. Hepatology. 2015 May;61(5):1643-50 - PubMed
  19. N Engl J Med. 2011 Sep 22;365(12):1118-27 - PubMed
  20. Gut. 2016 Jun;65(6):1035-41 - PubMed
  21. Transplantation. 2008 Jun 27;85(12):1726-32 - PubMed
  22. Hepatology. 2015 Jun;61(6):1968-77 - PubMed
  23. Am J Transplant. 2008 Apr;8(4):839-46 - PubMed

Publication Types